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Current cancer targeting relying on speciﬁc biological interaction between the cell surface antigen and
respective antibody or its analogue has proven to be eﬀective in the treatment of diﬀerent cancers;
however, this strategy has its own limitations, such as the heterogeneity of cancer cells and
immunogenicity of the biomacromolecule binding ligands. Bioorthogonal chemical conjugation has
emerged as an attractive alternative to biological interaction for in vivo cancer targeting. Here, we report
an in vivo cancer targeting strategy mediated by bioorthogonal oxime ligation. An oxyamine group, the
artiﬁcial target, is introduced onto 4T1 murine breast cancer cells through liposome delivery and fusion.
Poly(ethylene glycol)-polylactide (PEG-PLA) nanoparticles (NPs) are surface-functionalized with aldehyde
groups as targeting ligands. The improved in vivo cancer targeting of PEG-PLA NPs is achieved through
speciﬁc and eﬃcient chemical reaction between the oxyamine and aldehyde groups.Introduction
Current active cancer targeting mainly relies on specic and
strong biological interaction between a natural target, such as a
cancer cell surface antigen, and the corresponding bio-
macromolecule ligand, such as an antibody or its analogues.1–9
Although moderate cancer targeting eﬃciency can be achieved,
this strategy has its intrinsic limitations. First, the biological
interaction between antigen and antibody is generally weaker
than covalent binding, which exhibits dissociation constants Kd
below 108 M for many highly robust bioorthogonal reac-
tions.10–12 Second, limited numbers of receptors per cell and
heterogeneity of cancer cells could result in saturation and
insuﬃcient targeting or undesired oﬀ-targeting.13 Third, bio-
macromolecule binding ligands are generally more immuno-
genic and vulnerable than small molecule ligands and may be
subjected to enzymatic degradation in vivo; the large size rela-
tive to small molecule ligands and the undesired physi-
ochemical properties of the biomacromolecule binding ligandsEngineering, University of Illinois at
treet, Urbana, IL 61801, USA. E-mail:
; Tel: +1-217-244-3924
Guangdong Pharmaceutical University,
f Illinois at Urbana–Champaign, Urbana,
n (ESI) available: Synthesis and
oparticles, in vitro and in vivo tumor
aging and biodistribution. See DOI:may hinder their access to the target.14 The incorporation of
such ligands with anticancer drugs or nanomedicines also
requires sophisticated techniques to maintain the binding site
intact.15 Nanomedicine–ligand conjugates with a very high
surface density of biomacromolecule binding ligands may have
modied surface properties, resulting in reduced targeting
eﬀects and sometimes an undesired immune response.16
Bioorthogonal chemical conjugation with high specicity,
eﬃciency and biocompatibility has emerged as an attractive
alternative to specic biological interaction in vivo.17–21 Rather
than receptor–antibody interaction, such chemical conjugation
is a covalent binding between two bioorthogonal functional
groups. Compared with biological interactions, it has several
advantages. First, an extremely high aﬃnity between an
unnatural target and its respective ligand, which bear a pair of
bioorthogonal functional groups, could be achieved using
highly specic and robust bioorthogonal chemistry. Second, an
unnatural target containing one bioorthogonal functional
group of the pair can be articially introduced onto cancer cells
in a controlled manner through various cell surface engineering
methodologies.12,22 For example, metabolic glycoengineering
has been widely used to express azide groups on the cell
surface.22 A liposome fusion technique has successfully intro-
duced bioorthogonal functional groups on the cell
membrane.23,24 Third, small molecule ligands are generally
easily synthesized on a large scale, stable under physiological
conditions, easily conjugated with therapeutics including
nanomedicines and have minimum impact on the nanoparticle
(NP) properties due to their small size. Therefore, using bio-
orthogonal chemical conjugation could be a promising strategy
for in vivo cancer targeting.25–32This journal is © The Royal Society of Chemistry 2015
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View Article OnlineOxime ligation is a highly eﬃcient click-type bioorthogonal
condensation reaction between an oxyamine and an aldehyde
or a ketone.11,18,33 The formed oxime is highly stable toward
hydrolysis (Kd # 10
8 M) compared with the corresponding
imines or hydrazones.34 Thus, oxime ligation is compatible with
most biomolecule functionalities, including amines, and ideally
suited for application in living systems.23,35,36 However, in vivo
cancer targeting using an oxime ligation reaction has not been
reported. Herein, we report a novel chemical conjugation
mediated in vivo cancer targeting of poly(ethylene glycol)-b-
polylactide (PEG-PLA) NPs through bioorthogonal oxime liga-
tion (Scheme 1a). To prove the concept, the articial target, an
oxyamine group, was labelled on 4T1 murine breast cancer cells
through liposome delivery and fusion. The cancer targeting
eﬃciency was evaluated in vitro and in vivo using PEG-PLA NPs
functionalized with aldehyde groups on the surface (Ald-NP,
Scheme 1b).
Results and discussion
Eﬀective surface engineering of target cancer cells to present
bioorthogonal function groups is the prerequisite for cancer
targeting via chemical conjugation. Metabolic glycoengineeringScheme 1 (a) Schematic illustration of cancer targeting of poly(ethylene
glycol)-b-polylactide nanoparticles surface-modiﬁed with aldehyde
groups (Ald-NPs) through bioorthogonal oxime ligation. Oxyamine (Oa)
groups were labelled on cancer cells through membrane fusion of
liposomes bearing Oa groups (Oa-Lip). (b) Preparation of Oa-Lip with
POPC/DOTAP lipids and Oa with a hydrophobic tail (Oa-C12); prepa-
ration of Ald-NP with Ald-PEG-PLA and PEG-PLA polymers through
nanoprecipitation.
This journal is © The Royal Society of Chemistry 2015has proven to be a powerful methodology to present glycan with
a specic chemical group on the plasma membrane. However,
this method perturbs cellular physiology and may have the risk
of interfering with signicant biochemical pathways or cellular
functions of normal cells when these glycans are oﬀ target.37
Inspired by the recent work of Yousaf and others,24,38,39 we
explored the use of tailored liposomes to introduce an oxyamine
group on cancer cells though liposome delivery and fusion. We
synthesized O-dodecyloxyamine (Oa-C12) and incorporated it
into a liposome composed of a neutral lipid, egg palmitoyl-
oleoyl phosphatidylcholine (POPC) and a cationic lipid,
1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) at a mole
ratio of Oa-C12 : POPC : DOTAP ¼ 17 : 81 : 2 (Oa-Lip, Scheme
1b). The hydrophobic tail facilitated the spontaneous insertion
of Oa-C12 into the liposome membrane.24 The cationic lipid,
DOTAP, was added to enhance the interaction between the
synthesized Oa-Lip and negatively charged cell membrane
through electrostatic destabilization and thus increase the
liposome fusion and presentation of Oa groups on cell surface.
The formulated Oa-Lip had a hydrodynamic size of 136 nm
determined by dynamic light scattering (DLS) and transmission
electronic microscopy (TEM) (Fig. S1†). They also exhibited a
positive z-potential on the surface (12.3 mV, Table S1†) at
neutral pH owing to Oa-C12 and DOTAP.
We next used the Oa-Lip to engineer the 4T1 murine breast
cancer cell surface. In order to verify the successful cell surface
labelling, we rst conjugated a uorescent dye, rhodamine
(Rhd), to Oa-C12 to prepare Rhd-C12 and formulated the uo-
rescent liposome with POPC/DOTAP at the same mole ratio
(Rhd-Lip, Fig. S3a†). Rhd-Lips were then added to the 4T1 cells
and incubated in cell culture for 4 h (Fig. S3b†). The high
uorescence signal of Rhd shown in the confocal microscopy
image indicates the successful Rhd-Lip fusion and display of
Rhd-C12 on the 4T1 cells (Fig. S3c†). Direct addition of Rhd-C12
to the cell culture only resulted in minimum cell surface
labelling of uorescence suggesting the importance of the
liposome binding and fusion process.23,24 Furthermore, we
investigated whether the Oa groups displayed on the cell surface
were still active for oxime ligation. The 4T1 cell surface was
engineered with Oa-Lip similarly to present Oa groups on the
4T1 cell membrane (denoted as o4T1). Rhd dye bearing an
aldehyde group (Ald-Rhd) was subsequently added aer
washing oﬀ the excess Oa-Lip (Fig. S4a†). A markedly increased
uorescence signal was observed on the 4T1 cells with surface-
expressed Oa groups (o4T1) through the specic oxime ligation
with Ald-Rhd. In contrast, the o4T1 cells treated with non-
functional Rhd or native 4T1 cells treated with Ald-Rhd resulted
in a limited level of uorescence signal likely due to the
nonspecic and poorly eﬃcient conjugation or adsorption
(Fig. S4b†). Therefore, these results demonstrated that the
cancer cell surface could be eﬀectively engineered using a
liposome fusion strategy to express chemically active Oa groups
to further facilitate specic oxime ligation on the cell
membrane.
Intracellular uorescence was observed during the liposome
fusion process suggesting endocytosis of these liposomes or
their components may occur aer membrane fusion (Fig. S3c†).Chem. Sci., 2015, 6, 2182–2186 | 2183
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View Article OnlineThis could provide a possible method for internal membrane
engineering for intracellular targeting.24 However, it was
noticed that suﬃcient functional groups were present on cell
surface to facilitate the oxime ligation with the corresponding
ligands (Fig. S4b†). Such intracellular membrane labelling may
be benecial in the scenario of targeted intracellular drug
delivery.
Next, we studied the in vitro cancer cell targeting of the
nanomedicine toward 4T1 cells using the oxime ligation reac-
tion. PEG and PLA are highly biocompatible polymers widely
used in the formulation of polymeric nanomedicines for cancer
therapy. Small molecule anticancer drugs could be easily
incorporated into the PEG-PLA NPs prepared with the block
copolymer via physical encapsulation or chemical conjuga-
tion.40,41 We used a uorescent dye, Cy5, as a model drug to
uorescently label the NPs for the cancer cell binding and
internalization study.42 To introduce Ald groups to the NP
surface, a block polymer of Ald functionalized PEG-PLA was
co-precipitated with PEG-PLA at a 1 : 1 weight ratio to form
Ald-NPs (Scheme 1b). The resulting Ald-NPs were about 119 nm
in size with a narrow size distribution (Fig. S2†). Native 4T1 or
o4T1 cells were then treated with Cy5 labeled NPs or Ald-NPs
and analyzed by confocal uorescence microscopy and ow
cytometry (Fig. 1). Native 4T1 cells incubated with PEG-PLA NPs
showed minimum cell binding and/or internalization (Fig. 1a).
Native 4T1 cells treated with Ald-NPs or o4T1 cells treated with
NPs without Ald on the surface showed a slightly higher level of
NP binding or uptake. The former may be due to some non-
specic reactions between the cell surface groups and Ald; the
latter could be the result of increased electrostatic interaction
between the surface Oa groups on o4T1 and the negativelyFig. 1 In vitro cancer cell targeting through oxime ligation. (a)
Confocal microscopic images of native 4T1 cells (4T1) or 4T1 cells with
surface expressed Oa groups (o4T1) treated with Cy5 labeled PEG-PLA
NPs (red) without or with Ald groups (denoted as NP and Ald-NP
respectively). The nuclei were stained with 40,6-diamidino-2-phenyl-
indole (DAPI) (blue). Scale bar: 5 mm. (b) Flow cytometry analyses of the
cellular binding and/or internalization of the NPs. (c) The quantiﬁcation
ofmean ﬂuorescence intensity in the ﬂow cytometry analyses (average
 SD; n ¼ 3).
2184 | Chem. Sci., 2015, 6, 2182–2186charged NPs (10.0 mV z-potential, Table S1†). When the o4T1
cells were treated with Ald-NPs, the cellular binding and/or
internalization was remarkably enhanced, likely because of the
specic and eﬃcient oxime ligation between the cell surface Oa
groups and Ald groups on Ald-NPs. Further quantication with
ow cytometry indicated a 2.6 fold increase in cell uptake of
o4T1 + Ald-NP compared with 4T1 + Ald-NP or o4T1 + NP, and a
4.2 fold increase compared with 4T1 + NP (Fig. 1b and c). The
results demonstrated that Oa–Ald recognition largely improves
cancer targeting via oxime ligation. It is also noticeable that a
signicant amount of the Ald-NPs were internalized into the
o4T1 cells. These observations indicate that the bioorthogonal
oxime ligation mediated not only the enhanced cancer cell–NP
binding but also the subsequent endocytosis of the NPs, which
is important for intracellular delivery of anticancer drugs to
achieve improved eﬃcacy against cancer cells.
We next evaluated the potential of oxime ligation for in vivo
cancer targeting. A subcutaneous 4T1 tumor model was estab-
lished on both anks of BALB/c mice. To prove the concept of
cancer cell surface engineering in vivo using the liposome
fusion technique and subsequent oxime ligation mediated
cancer targeting, we injected Oa-Lip intratumorally to label the
cancer cells in vivo. We rst veried the cancer cell surface
presentation of Oa groups inside the tumor tissues by injecting
uorescent Rhd-Lip intratumorally (Fig. S5a†). Fluorescently
labeled Oa-C12 was expected to be present on the cell
membrane inside the tumors through a similar liposome fusion
process observed in vitro. The tumors were collected 4 h or 24 h
post injection (p.i.), sectioned and analyzed by confocal
microscopy. As expected, a strong orescence signal from Rhd-
C12 was observed on the tumor cells at 4 h p.i. indicating the
successful introduction of functional groups on plasma
membrane in vivo through liposome delivery and membrane
fusion (Fig. S5b†). The uorescence decreased at 24 h p.i. likely
due to the clearance or metabolizing of the Rhd-C12 (Fig. S5b†).
We then injected the Oa-Lip intratumorally to the le tumor
(oTM) and PBS to the right one (TM) as a control (Fig. 2a) to
study the cancer targeting in vivo. The mice received intrave-
nous injection of Ald-NPs through tail veins 4 h aer the
introduction of Oa groups to the cells in the le tumors. In
order to monitor the in vivo tumor targeting kinetics, the
injected Ald-NPs were radio labeled with the isotope 64Cu using
a chelating ligand, DOTA, conjugated to the polymer chain for
dynamic positron emission tomography (PET) imaging over time
without sacricing the animals.43 All of the PET images were
overlaid with micro X-ray computed tomography (CT) images to
identify the position of the tumors (yellow circles and arrows in
Fig. 2a). Ald-NPs started to accumulate in oTM (2.8% I.D. g1) as
early as 1 h p.i. with 75.0% higher amount than that in TM (1.6%
I.D. g1). At 6 h p.i., the accumulation of Ald-NPs in oTM
increased to 5.5% I.D. g1, which was 37.5% higher than that in
TM (4.0% I.D. g1) with statistical signicance (Fig. 2b). The
three-dimensional reconstructed image (Fig. 2c) also provides
evidence for the signicantly enhanced accumulation of Ald-NPs
in oTM at 6 h p.i. At 24 h p.i., the tumor accumulation decreased
slightly on both sides compared with the amount at 6 h.
However, Ald-NPs persisted in oTM (3.6% I.D. g1) with anThis journal is © The Royal Society of Chemistry 2015
Fig. 2 In vivo cancer targeting through oxime ligation. (a) In vivo
whole-body dynamic PET/CT imaging of mice performed at 1, 6 and
24 h post NP injection to assess the accumulation of the Ald-NPs in the
left tumors labeled with Oa groups (oTM) and the right tumors (TM).
Tumors are indicated with yellow circles and arrows. (b) Quantiﬁcation
of the accumulation of 64Cu labeled Ald-NPs in the tumors over time
achieved by selecting the three-dimensional regions of interest in the
PET images and analyzing with the instrument software (average SD;
n ¼ 3; *p < 0.05). (c) Corresponding three dimensional PET/CT image
at 6 h p.i. showing enhanced accumulation of the Ald-NPs in the left
oTM.
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View Article Onlineamount 63.6% higher than that in TM (2.2% I.D. g1). These
results were conrmed by ex vivo measurement of the accumu-
lation of Ald-NPs in the excised tumors using a g-counter
(Fig. S6†). A similar experiment was performed whereby PEG-
PLA NPs without Ald groups on the surface were intravenously
injected into the mice bearing oTM and TM on each side. No
signicant diﬀerence in tumor accumulation of the NPs on the
two sides at 6 h or 24 h p.i. was observed (Fig. S7†) and the
accumulation of NPs in oTM was lower than that of the Ald-NPs
in oTM (Fig. S7† vs. Fig. 2b) indicating that the specic oxime
ligation was responsible for the increased tumor accumulation
and retention of Ald-NPs in oTM. These observations suggest
that in vivo cancer targeting could indeed be achieved using
bioorthogonal oxime ligation.
Cancer pretargeting strategies, which use antibodies to
target tumors for the rst step, followed by the second step of
using an imaging or therapeutic agent to bind to the tumor-
localized antibody, have proven to be superior to direct target-
ing by the conventional antibody conjugates in clinical
trials.44–46 Here, we described a similar two-step pretargeting
strategy, using liposome delivery and fusion for the rst-step
passive cancer targeting, and then guiding the nanomedicine to
the tumor through an oxime ligation reaction with the bio-
orthogonal groups introduced by the liposome. Compared with
the antibody-based pretargeting method, our strategy does not
involve any potentially immunogenic biomacromolecules or
depend on the heterogeneous cell surface antigens.14 As a proof
of concept, we used intratumoral injection of Oa-Lip to label the
cancer cells in vivo. However, liposomes bearing Oa groupsThis journal is © The Royal Society of Chemistry 2015could also be dosed systemically in the pretargeting step to
achieve suﬃcient presentation of the target functional groups
on the plasma membrane inside tumors via a passive tumor
targeting mechanism, i.e. an enhanced permeation and reten-
tion (EPR) eﬀect of the nanomedicine, followed by the admin-
istration of the second component, the drug-containing
nanomedicine modied with the ligand functional groups.47Conclusions
In conclusion, we demonstrated a novel cancer targeting
strategy in vitro and in vivo using a bioorthogonal oxime ligation
reaction. One bioorthogonal functional group (i.e. Oa) as an
unnatural target was eﬃciently introduced to cancer cells using
a liposomal delivery and fusion technique. Ald groups, as the
targeting ligand for Oa, could be easily synthesized and incor-
porated into nanomedicines. Specic and eﬃcient oxime liga-
tion led to markedly improved cancer targeting in vivo through
chemical Oa–Ald recognition. Given the versatility of the lipo-
some fusion method for diﬀerent bioorthogonal groups and the
large variety of bioorthogonal chemistry available, we anticipate
that many bioorthogonal reaction-mediated cancer targeting
strategies can be easily developed, optimized and compared.
Future eﬃcacy studies using targeted, drug-loaded biocompat-
ible nanomedicine combined with the cancer pretargeting
method through systemic delivery will be important to further
evaluate the potential of such strategies for targeted cancer
therapy.Acknowledgements
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